443 related articles for article (PubMed ID: 30790150)
1. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
2. Impact of ALK Inhibitors in Patients With
Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
[TBL] [Abstract][Full Text] [Related]
3. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
4. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib.
Sunga CGG; Higgins MS; Ricciotti RW; Liu YJ; Cranmer LD
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1792. PubMed ID: 36754839
[TBL] [Abstract][Full Text] [Related]
6. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
7. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
8. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
10. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
Saiki M; Ohyanagi F; Ariyasu R; Koyama J; Sonoda T; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Ninomiya H; Ishikawa Y; Nishio M
Jpn J Clin Oncol; 2017 Dec; 47(12):1189-1192. PubMed ID: 28977547
[TBL] [Abstract][Full Text] [Related]
11. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract][Full Text] [Related]
12. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
[No Abstract] [Full Text] [Related]
13. Anaplastic Lymphoma Kinase Mutation (
Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
[No Abstract] [Full Text] [Related]
14. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
17. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract][Full Text] [Related]
18. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K
Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
20. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]